EAU 2017: State-of-the-art Lecture: How will Immunotherapy Change the Treatment Paradigm? – UroToday
|
EAU 2017: State-of-the-art Lecture: How will Immunotherapy Change the Treatment Paradigm?
UroToday Dr. Jones concluded this thought provoking session by noting that immunotherapy is here to stay as second line treatment and we urgently need to understand patient selection in the first line setting. Ultimately, we need careful research to “harness … |
新浪网 |
上海生科院利用CRISPR/Cpf1系统简单高效实现水稻多基因定点编辑
新浪网 3月19日，《分子植物》（Molecular Plant）杂志在线发表了中国科学院上海生命科学研究院植物逆境生物学研究中心朱健康研究组题为Multiplex Gene Editing in Rice using the CRISPR-Cpf1 System 的研究论文。该工作在水 … 张锋团队这次输了？CRISPR/Cas9专利之争再起风云搜狐 |
|
EAU 2017: State-of-the-art Lecture Immunotherapy: Open Questions and Trials
UroToday EAU 2017: State-of-the-art Lecture Immunotherapy: Open Questions and Trials. Published 26 March 2017; London, England (UroToday.com) At this morning’s EAU 2017 thematic session on Immuno-oncology, Dr. Laurence Albiges provided a very … |
|
State-of-the-art Lecture Immunotherapy: Impact from Surgeon’s Point of View
UroToday With regards to adjuvant immunotherapy, the Immotion Trial 010 is currently recruiting for 12 months of adjuvant atezolizumab vs placebo for all renal cancer histologies (≥pT1, any T and positive N). In the neoadjuvant setting, preliminary data from a … |
Corvallis Gazette Times |
Is Alzheimer’s treatment of injecting stem cells into the brain a breakthrough or quackery?
Corvallis Gazette Times Duma conducted phase one of clinical trials on a new treatment for Alzheimer’s disease called intra-cerebro ventricular injection of autologous mesenchymal stem cells. He basically took fat cells from Jack Sage’s body, spun them down to stem cells and … |